Medical Encyclopedia |
|
Other encyclopedia topics: | A-Ag Ah-Ap Aq-Az B-Bk Bl-Bz C-Cg Ch-Co Cp-Cz D-Di Dj-Dz E-Ep Eq-Ez F G H-Hf Hg-Hz I-In Io-Iz J K L-Ln Lo-Lz M-Mf Mg-Mz N O P-Pl Pm-Pz Q R S-Sh Si-Sp Sq-Sz T-Tn To-Tz U V W X Y Z 0-9 |
Contents of this page: | |
Alternative Names
Chorioblastoma; Trophoblastic tumor; Chorioepithelioma; Gestational trophoblastic neoplasiaDefinition Return to top
Choriocarcinoma is quick-growing form of cancer that occurs in a woman's uterus (womb). The abnormal cells start in the tissue that would normally become the placenta, the organ that develops during pregnancy to feed the fetus.
Choriocarcinoma is a type of gestational trophoblastic disease.
See also:
Causes Return to top
Choriocarcinoma is an uncommon, but very often curable cancer associated with pregnancy. A baby may or may not develop in these types of pregnancy.
The cancer may develop after a normal pregnancy, however, it is most often associated with a complete hydatidiform mole. The abnormal tissue from the mole can continue to grow even after it is removed and can turn into cancer. About half of all women with a choriocarcinoma had a hydatidiform mole, or molar pregnancy.
Choriocarcinomas may also occur after an abortion, ectopic pregnancy, or genital tumor.
Symptoms Return to top
A possible symptom is continued vaginal bleeding in a woman with a recent history of hydatidiform mole, abortion, or pregnancy.
Additional symptoms may include:
Exams and Tests Return to top
A pregnancy test will be positive even when you are not pregnant. Pregnancy hormone (HCG) levels will be presistently high.
A pelvic examination may reveal continued uterine swelling or a tumor.
Blood tests that may be done include:
Imaging tests that may be done include:
Treatment Return to top
After an initial diagnosis, a careful history and examination are done to make sure the cancer has not spread to other organs. Chemotherapy is the main type of treatment.
A hysterectomy and radiation therapy are rarely needed.
Support Groups Return to top
For additional information, see cancer resources.
Outlook (Prognosis) Return to top
Most women whose cancer has not spread can be cured and will maintain reproductive function.
The condition is harder to cure if the cancer has spread and one of more of the following events occur:
Many women (about 70%) who initially have a poor outlook go into remission (a disease-free state).
Possible Complications Return to top
A choriocarcinoma may come back after treatment, usually within several months but possibly as late as 3 years. Complications associated with chemotherapy can also occur.
When to Contact a Medical Professional Return to top
Call for an appointment with your health care provider if symptoms arise within 1 year after hydatidiform mole, abortion (including miscarriage), or term pregnancy.
Prevention Return to top
Careful monitoring after the removal of hydatidiform mole or termination of pregnancy can lead to early diagnosis of a choriocarcinoma, which improves outcome.
References Return to top
Berkowitz RS, Goldstein DP. Gestational trophoblastic diseases. In: Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME, eds. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:1055-1076.
Kavanagh JJ, Gershenson DM. Gestational Trophoblastic Disease: Hydatidiform Mole, Nonmetastatic and Metastatic Gestational Trophoblastic Tumor: Diagnosis and Management. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM. Comprehensive Gynecology. 5th ed. Philadelphia, Pa: Mosby Elsevier; 2007: chap. 35.
Update Date: 5/26/2008 Updated by: Linda Vorvick, MD, Seattle Site Coordinator, Lecturer, Pathophysiology, MEDEX Northwest Division of Physician Assistant Studies, University of Washington School of Medicine; and Susan Storck, MD, FACOG, Clinical Teaching Faculty, Department of Obstetrics and Gynecology, University of Washington School of Medicine; Chief, Eastside Department of Obstetrics and Gynecology, Group Health Cooperative of Puget Sound, Redmond, Washington. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.